Encapsulated porcine islet transplantation: an evolving therapy for the treatment of type I diabetes.
Expert Opin Biol Ther
; 9(1): 29-44, 2009 Jan.
Article
in En
| MEDLINE
| ID: mdl-19063691
ABSTRACT
BACKGROUND:
Allogeneic tissue-based therapies for Type I diabetes have demonstrated efficacy but are limited due to tissue-sourcing constraints, as the number of patients exceeds that of tissue donors. Porcine islets derived from designated pathogen-free sources could be an alternative, particularly if delivered in a way that evades the host immune system's rejection.METHODS:
This review focuses on approaches designed to protect xenogeneic islets from immune rejection by provision of perm-selective barriers.RESULTS:
Designated pathogen-free herds could provide a supply of wild-type porcine islets that are well tolerated when administered in a suitable protective delivery vehicle. Such barrier systems have enabled amelioration of diabetes in a variety of animal models and preliminary evidence suggests that similar results could be attained in humans.CONCLUSION:
With advances in biomaterial design, source tissue selection, and the evolution of critical cell processing techniques, contemporary encapsulated porcine islet therapies offer a new level of clinical promise.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Swine
/
Transplantation, Heterologous
/
Islets of Langerhans Transplantation
/
Diabetes Mellitus, Type 1
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Opin Biol Ther
Journal subject:
BIOLOGIA
/
TERAPEUTICA
Year:
2009
Document type:
Article
Affiliation country: